Table 2.

Summary of adverse events through the current data-cut^a (safety set)

	Overall (N = 10)
	n (%)	Events
Any AE	10 (100)	66
Any serious AE	1 (10.0)	5
TESAEs resulting in drug discontinuation	0	0
TEAEs resulting in trial discontinuation	0	0
TEAEs during trial drug infusion	2 (20.0)	4
TESAEs during trial drug infusion	0	0
Treatment-related AEs	2 (20.0)	4
Meningococcal infections	0	0
Deaths	0	0

^aCurrent data-cut at median follow-up duration of 50.2 weeks

AEs were coded using the MedDRA version 21.0. The severity of AEs was graded using the CTCAE version 4.03

AE adverse event, TEAE treatment-emergent adverse event, TESAE treatment-emergent serious adverse event